Drug intelligence / Profile preview

Lysomin

Development stage: Unknown
Lead developer: Arya Pharma Lab
Modality: Small Molecules
Administration: Oral

Overview

**Lysomin** is an oral nutritional syrup marketed by Arya Pharma Lab in Nepal. It is a fixed-dose combination of thiamine hydrochloride, pyridoxine hydrochloride, cyanocobalamin, and L-lysine. The B vitamins provide essential vitamin cofactors involved in carbohydrate and amino-acid metabolism, neurologic function, and hematopoiesis, while lysine is an essential amino acid used to support protein synthesis and nutrition. It is marketed for nutritional supplementation and prevention or management of vitamin B deficiency.

Brand names: Lysomin
Other names: Thiamine hydrochloride + Pyridoxine hydrochloride + Cyanocobalamin + L-lysine

Beyond the preview

Go deeper on Lysomin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysomin.

Explore the full profile